Sequence: Stearyl-FLKLLKKFLFLKLLKKFL-amide
SCO (splice-correcting oligonucleotide / ASO)
| Experiment Id | EXP001825 |
|---|---|
| Paper | Magnetic Nanoparticle Assisted Self-assembly of Cell Penetrating Peptides-Oligonucleotides Complexes |
| Peptide | PF221 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | CPP 10.5 µL used in formulation (per methods) |
| Rna Concentration | SCO 100 nM typical (varied 50–200 nM in optimization; MNP amount 4–8 µL) |
| Mixing Ratio | MR 10:1 (CPP:SCO) with MNPs co-incubated |
| Formulation Format | CPP/SCO/MNP ternary nanocomplex (non-covalent) |
| Formulation Components | PF221 + SCO + Fe3O4 MNPs (4 µL of 1 mg/mL stock) self-assembled in MQ water (pH~5) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa puLuc 705 cells (96-well splice correction, 24 h) |
| Animal Model | |
| Administration Route | |
| Output Type | Splice correction (luciferase activity) |
| Output Value | MNP incorporation increases activity; PF14-SCO-MNP up to ~4× vs PF14-SCO |
| Output Units | |
| Output Notes | Reported that MNPs improve PF14-SCO efficiency (~4×) with near-100% cell population transfected; SCARA inhibitors reduce PF14-SCO-MNP activity >90%. |
| Toxicity Notes | No significant toxicity reported (WST-1; supplementary). |
| Curation Notes |